KATHRYN FURGE: Open Payments
NPI 1386274215 · DANVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$930 in 47 payments from 16 companies in 2025. Trend: 2023 $2,611 · 2024 $1,989 · 2025 $930
Food & beverage: $930
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $246 |
| PFIZER INC. | 5 | $100 |
| Amgen Inc. | 1 | $90 |
| Celgene Corporation | 2 | $50 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Gilead Sciences, Inc. | 2 | $49 |
| Merck Sharp & Dohme LLC | 2 | $47 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $42 |
| Janssen Biotech, Inc. | 1 | $42 |
Products named: KISQALI, LUMAKRAS, PADCEV, LUTATHERA, REBLOZYL, Trodelvy, KEYTRUDA, OPDIVO.
Industry payments across IN — which companies pay providers there.
